Wellington Management Group LLP Grows Stock Holdings in Altimmune, Inc. $ALT

Wellington Management Group LLP boosted its stake in Altimmune, Inc. (NASDAQ:ALT) by 9.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 224,954 shares of the company’s stock after acquiring an additional 19,721 shares during the period. Wellington Management Group LLP owned about 0.29% of Altimmune worth $1,125,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Ameriprise Financial Inc. lifted its position in Altimmune by 35.6% in the fourth quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company’s stock valued at $37,888,000 after acquiring an additional 1,378,854 shares during the last quarter. Bellevue Group AG lifted its position in Altimmune by 9.5% in the fourth quarter. Bellevue Group AG now owns 945,446 shares of the company’s stock valued at $6,817,000 after acquiring an additional 81,786 shares during the last quarter. Northern Trust Corp lifted its position in Altimmune by 5.7% in the fourth quarter. Northern Trust Corp now owns 665,916 shares of the company’s stock valued at $4,801,000 after acquiring an additional 35,918 shares during the last quarter. Two Sigma Investments LP lifted its position in Altimmune by 33.2% in the fourth quarter. Two Sigma Investments LP now owns 605,303 shares of the company’s stock valued at $4,364,000 after acquiring an additional 151,001 shares during the last quarter. Finally, Ensign Peak Advisors Inc lifted its position in Altimmune by 39.2% in the fourth quarter. Ensign Peak Advisors Inc now owns 454,981 shares of the company’s stock valued at $3,280,000 after acquiring an additional 128,204 shares during the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune Trading Up 3.2%

NASDAQ ALT opened at $3.83 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 20.44 and a current ratio of 20.44. The firm has a market cap of $338.02 million, a PE ratio of -3.25 and a beta of 0.18. Altimmune, Inc. has a one year low of $2.90 and a one year high of $11.16. The firm’s fifty day moving average is $4.12 and its two-hundred day moving average is $5.05.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.05. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Analysts expect that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ALT shares. The Goldman Sachs Group raised shares of Altimmune to a “strong sell” rating in a research report on Thursday, July 10th. Wall Street Zen raised shares of Altimmune from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. UBS Group dropped their price objective on shares of Altimmune from $26.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. JMP Securities dropped their price objective on shares of Altimmune from $25.00 to $15.00 and set a “market outperform” rating on the stock in a research note on Thursday, July 10th. Finally, B. Riley dropped their price objective on shares of Altimmune from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $17.40.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.